Contineum Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 6, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item5. Other Information.
From time to time, our officers (as defined in Rule16a-1(f) of the Exchange Act) and directors* mayenter into Rule10b5*-1 or non-Rule10b5-1 trading arrangements (as each such term is defined in Item408 of Regulation S-K). During thethree months ended* September 30, 2024,*none of our officers or directors adopted or terminated any such trading arrangements except as set forth below:
| Name (Title) | Action Taken (Date of Action) | Type of Trading Arrangement | Nature of Trading Arrangement | Duration of Trading Arrangement | Aggregate Number of Securities |
|---|---|---|---|---|---|
| Carmine Stengone (President and Chief Executive Officer) | Adoption ( August 19, 2024) | Rule 10b5-1 trading arrangement* | Sale | Until November 19, 2025, or such earlier date upon which all transactions are completed or expire without execution | Up to 250,980 shares |
| Peter Slover (Chief Financial Officer) | Adoption ( August 19, 2024) | Rule 10b5-1 trading arrangement* | Sale | Until November 19, 2025, or such earlier date upon which all transactions are completed or expire without execution | Up to 41,780 shares |
| Daniel Lorrain, Ph.D. (Chief Scientific Officer) | Adoption ( August 19, 2024) | Rule 10b5-1 trading arrangement* | Sale | Until November 19, 2025, or such earlier date upon which all transactions are completed or expire without execution | Up to 188,325 shares |
| Stephen Huhn, M.D. (Chief Medical Officer and Senior Vice President, Clinical Development) | Adoption ( August 19, 2024) | Rule 10b5-1 trading arrangement* | Sale | Until November 19, 2025, or such earlier date upon which all transactions are completed or expire without execution | Up to 47,300 shares |
| John Healy (General Counsel and Corporate Secretary) | Adoption ( August 20, 2024) | Rule 10b5-1 trading arrangement* | Sale | Until November 19, 2025, or such earlier date upon which all transactions are completed or expire without execution | Up to 11,328 shares |
| Lori Lyons-Williams (Director) | Adoption ( August 21, 2024) | Rule 10b5-1 trading arrangement* | Sale | Until November 19, 2025, or such earlier date upon which all transactions are completed or expire without execution | Up to 11,784 shares |
- Intended to satisfy the affirmative defense of Rule10b5-1(c)
22
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.